Fidelity Advisor Biotechnology Fund - Class A (FBTAX)
Fund Assets | 1.50B |
Expense Ratio | 1.01% |
Min. Investment | $0.00 |
Turnover | n/a |
Dividend (ttm) | 1.63 |
Dividend Yield | 5.69% |
Dividend Growth | 418.10% |
Payout Frequency | Annual |
Ex-Dividend Date | Dec 26, 2024 |
Previous Close | 27.26 |
YTD Return | 0.22% |
1-Year Return | -10.56% |
5-Year Return | 36.49% |
52-Week Low | 25.97 |
52-Week High | 34.77 |
Beta (5Y) | 0.53 |
Holdings | 97 |
Inception Date | Dec 27, 2000 |
About FBTAX
The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments. The fund is non-diversified.
Performance
FBTAX had a total return of -10.56% in the past year. Since the fund's inception, the average annual return has been 6.72%, including dividends.
Top 10 Holdings
57.80% of assetsName | Symbol | Weight |
---|---|---|
AbbVie Inc. | ABBV | 21.42% |
Regeneron Pharmaceuticals, Inc. | REGN | 6.23% |
Amgen Inc. | AMGN | 5.86% |
Alnylam Pharmaceuticals, Inc. | ALNY | 5.23% |
Vertex Pharmaceuticals Incorporated | VRTX | 4.62% |
argenx SE | ARGX | 4.52% |
Ascendis Pharma A/S | ASND | 3.85% |
Vaxcyte, Inc. | PCVX | 2.25% |
Viridian Therapeutics, Inc. | VRDN | 1.93% |
Nuvalent, Inc. | NUVL | 1.90% |
Dividend History
Ex-Dividend | Amount | Pay Date |
---|---|---|
Dec 26, 2024 | $1.632 | Dec 27, 2024 |
Dec 21, 2023 | $0.315 | Dec 22, 2023 |
Dec 17, 2021 | $5.364 | Dec 20, 2021 |
Jul 9, 2021 | $0.103 | Jul 12, 2021 |
Dec 18, 2020 | $2.840 | Dec 21, 2020 |
Dec 20, 2019 | $1.880 | Dec 23, 2019 |